Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

National Registry of Interstitial Lung Disease from Pakistan.

Cureus·2021

Same author

Diagnostic Accuracy of Xpert MTB/RIF in Sputum Smear-Negative Pulmonary Tuberculosis.

Cureus·2019

Same author

Six-minute walk test performance in healthy adult Pakistani volunteers.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2013

Same author

Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2010

Same author

Variables predictive of outcome in patients with acute hypercapneic respiratory failure treated with noninvasive ventilation.

JPMA. The Journal of the Pakistan Medical Association·2010

Same author

Treatment outcome of multi-drug resistant tuberculosis in a tertiary care hospital in Karachi.

JPMA. The Journal of the Pakistan Medical Association·2009

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

New drugs in resistant tuberculosis.

Nisar Ahmed Rao¹

¹Department of Pulmonology, Ojha Institute of Chest Diseases, Dow University of Health Sciences, Karachi.

JPMA. the Journal of the Pakistan Medical Association

|June 19, 2007

Summary

Drug-resistant tuberculosis (TB) is a growing global health crisis. This article raises awareness of current and emerging treatments for multidrug-resistant TB (MDR-TB), emphasizing physician consultation.

Area of Science:

Infectious Diseases
Public Health
Pharmacology

Background:

The World Health Organization estimates up to 50 million people globally may have drug-resistant tuberculosis (TB).
Multidrug-resistant TB (MDR-TB) has a high fatality rate, ranging from 20% to 80%.
Drug-resistant TB cases are increasing in Pakistan due to factors like improper prescription, poor compliance, and over-the-counter anti-TB drug sales.

Purpose of the Study:

To raise awareness regarding available second-line drugs for drug-resistant TB.
To inform about anti-TB drugs currently in the development pipeline.
To highlight the challenges in managing resistant tuberculosis and the importance of expert consultation.

Main Methods:

Review of existing literature on drug-resistant TB treatments.

Related Experiment Videos

Last Updated: Jul 14, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Analysis of current trends in TB drug resistance.

Information gathering on anti-TB drugs in various stages of development.

Main Results:

There are currently 27 potential anti-TB drugs in development.
The article emphasizes the need for physician consultation for managing drug-resistant TB.
A common error in treatment is adding a single drug to a failing regimen.

Conclusions:

Managing drug-resistant TB requires specialized knowledge and careful treatment strategies.
Physicians experienced in treating resistant TB should be consulted.
The development pipeline shows promise for new anti-TB therapies, with an aim for market availability by 2010.